Clausse Maria, Díaz Alejandra G, Pardo Romina P, Zylberman Vanesa, Goldbaum Fernando A, Estein Silvia M
Laboratorio de Inmunología, Departamento de Sanidad Animal y Medicina Preventiva (SAMP), Centro de Investigación Veterinaria de Tandil (CIVETAN-CONICET-CIC), Facultad de Ciencias Veterinarias, Universidad Nacional del Centro de la Provincia de Buenos Aires (UNCPBA), Tandil, Argentina; Consejo Nacional de Investigaciones Científicas (CONICET), Argentina.
Laboratorio de Inmunología, Departamento de Sanidad Animal y Medicina Preventiva (SAMP), Centro de Investigación Veterinaria de Tandil (CIVETAN-CONICET-CIC), Facultad de Ciencias Veterinarias, Universidad Nacional del Centro de la Provincia de Buenos Aires (UNCPBA), Tandil, Argentina; Consejo Nacional de Investigaciones Científicas (CONICET), Argentina.
Vet Immunol Immunopathol. 2017 Feb;184:36-41. doi: 10.1016/j.vetimm.2016.11.004. Epub 2016 Dec 5.
Polymeric antigen BLSOmp31 is an immunogenic vaccine candidate that confers protection against Brucella canis in mice. In this preliminary study, the immunogenicity and safety of BLSOmp31 adsorbed to aluminum hydroxide gel (BLSOmp31-AH) were evaluated in Beagle dogs. In addition, the potential to elicit serum antibodies with complement-dependent bactericidal activity and/or to enhance phagocytosis by neutrophils were analyzed. Dogs were immunized three times with BLSOmp31-AH by subcutaneous route, followed by an annual booster. The vaccine elicited specific antibodies 3 weeks after the first immunization. Annual booster induced comparable antibody response as the primary series. Humoral immune response stimulated by BLSOmp31-AH did not interfere with routine agglutination test for canine brucellosis. Antibodies demonstrated a high complement-dependent bactericidal activity against B. canis. Moreover, opsonization by immune serum not only stimulated binding and uptake of the bacteria by neutrophils but effectively enhanced the destruction of B. canis. Specific IgG was detected in 3/4 immunized dogs in preputial secretions. The antibody profile corresponded to a marked Th2 response, since IgG1 prevailed over IgG2 and cellular immune response was not detected in vitro or in vivo. These results require further evaluation in larger field studies to establish the full prophylactic activity of BLSOmp31 against canine brucellosis.
聚合抗原BLSOmp31是一种具有免疫原性的候选疫苗,可使小鼠对犬布鲁氏菌产生保护作用。在这项初步研究中,对氢氧化铝凝胶吸附的BLSOmp31(BLSOmp31-AH)在比格犬中的免疫原性和安全性进行了评估。此外,还分析了诱导具有补体依赖性杀菌活性的血清抗体和/或增强中性粒细胞吞噬作用的潜力。通过皮下途径用BLSOmp31-AH对犬进行三次免疫,随后每年进行一次加强免疫。疫苗在首次免疫后3周诱导产生特异性抗体。每年的加强免疫诱导的抗体反应与初次免疫系列相当。BLSOmp31-AH刺激的体液免疫反应不干扰犬布鲁氏菌病的常规凝集试验。抗体对犬布鲁氏菌表现出高补体依赖性杀菌活性。此外,免疫血清的调理作用不仅刺激了中性粒细胞对细菌的结合和摄取,而且有效地增强了对犬布鲁氏菌的破坏。在4只免疫犬中的3只的包皮分泌物中检测到特异性IgG。抗体谱对应于明显的Th2反应,因为IgG1比IgG2占优势,并且在体外或体内均未检测到细胞免疫反应。这些结果需要在更大规模的现场研究中进一步评估,以确定BLSOmp31对犬布鲁氏菌病的完全预防活性。